⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 12, 2024ClimactericOpen Access

Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan

Kiyoshi Takamatsu Takashi Miki Kentaro Miyazaki Atsuki Hashimoto Weizhong He Xuegong Wang

View Full Paper

Ask AI

Bookmark

Share

Abstract

Objective The phase II STARLIGHT study was conducted to investigate the efficacy/safety of fezolinetant in Japanese women and identify the optimal dose for future evaluation.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Takamatsu et al. (2024) studied this question.

synapsesocial.com/papers/68e650a0b6db6435875e0c05 https://doi.org/10.1080/13697137.2024.2356854

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Patient-reported outcome data from a randomized phase II study (STARLIGHT) of fezolinetant in women in Japan with vasomotor symptoms associated with menopauseRCT · 2026
2Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I)2024 · 29 citations
3Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 StudiesRCT · 2024 · 15 citations
4Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial2024 · 18 citations
5Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a TrialRCT · 2019 · 153 citations